Skip to main content
Top
Published in: Familial Cancer 2/2011

01-06-2011

German national case collection for familial pancreatic cancer (FaPaCa): ten years experience

Authors: Ralph Schneider, Emily P. Slater, Mercede Sina, Nils Habbe, Volker Fendrich, Elvira Matthäi, Peter Langer, Detlef K. Bartsch

Published in: Familial Cancer | Issue 2/2011

Login to get access

Abstract

Familial pancreatic cancer (FPC) is a rare hereditary tumor syndrome. The 10-years experience of the national case collection for familial pancreatic cancer of Germany (FaPaCa) is reported. Since 1999 FaPaCa has collected families with at least two first-degree relatives with confirmed pancreatic cancer (PC), who did not fulfill the criteria of other hereditary tumor syndromes. Histopathological verification of tumor diagnoses, and genetic counseling were prerequisites for enrollment of families in FaPaCa. 94 of 452 evaluated families fulfilled the criteria for partaking in FaPaCa. PC represented the sole tumor entity in 38 (40%) families. In 56 families additional tumor types occurred, including breast cancer (n = 28), colon cancer (n = 20) and lung cancer (n = 11). In 70 (74%) families the pattern of inheritance was consistent with an autosomal dominant trait. Compared to the preceding generation, a younger age of onset was observed in the offspring of PC patients (median: 57 vs. 69 years), indicating anticipation. Mutation analyses of BRCA2, PALB2, CDKN2a, RNASEL, STK11, NOD2, CHEK2 and PALLD, revealed deleterious causative germline mutations of BRCA2 and PALB2 in 2 of 70 (3%) and 2 of 41 (4.9%) German FPC families, respectively. Prospective PC screening with EUS, MRI and MRCP detected precancerous lesions (IPMN, multifocal PanIN2/3) or carcinoma in 5.5% (4 of 72) to 12.5% (9 of 72) of individuals at risk, depending on histological verification. Appropriate inclusion of families at high risk for PC in registries, such as FaPaCa, provides a unique and excellent tool to gain clinical and genetic knowledge of FPC. Focused research projects can be conducted most efficiently, when data of different FPC registries are combined.
Literature
1.
2.
go back to reference Cleary SP, Gryfe R, Guindi M et al (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731PubMedCrossRef Cleary SP, Gryfe R, Guindi M et al (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198:722–731PubMedCrossRef
3.
go back to reference Hruban RH, Petersen GM, Ha PK et al (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 7:1–23PubMed Hruban RH, Petersen GM, Ha PK et al (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 7:1–23PubMed
4.
5.
go back to reference Applebaum SE, Kant JA, Whitcomb DC et al (2000) Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases. Med Clin North Am 84:575–588 viiiPubMedCrossRef Applebaum SE, Kant JA, Whitcomb DC et al (2000) Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases. Med Clin North Am 84:575–588 viiiPubMedCrossRef
6.
go back to reference Ehrenthal D, Haeger L, Griffin T et al (1987) Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 59:1661–1664PubMedCrossRef Ehrenthal D, Haeger L, Griffin T et al (1987) Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 59:1661–1664PubMedCrossRef
7.
go back to reference MacDermott RP, Kramer P (1973) Adenocarcinoma of the pancreas in four siblings. Gastroenterology 65:137–139PubMed MacDermott RP, Kramer P (1973) Adenocarcinoma of the pancreas in four siblings. Gastroenterology 65:137–139PubMed
8.
9.
go back to reference Lynch HT, Lanspa SJ, Fitzgibbons RJ Jr et al (1989) Familial pancreatic cancer (part 1): genetic pathology review. Nebr Med J 74:109–112PubMed Lynch HT, Lanspa SJ, Fitzgibbons RJ Jr et al (1989) Familial pancreatic cancer (part 1): genetic pathology review. Nebr Med J 74:109–112PubMed
10.
go back to reference Bartsch DK, Sina-Frey M, Ziegler A et al (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510–516PubMedCrossRef Bartsch DK, Sina-Frey M, Ziegler A et al (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510–516PubMedCrossRef
11.
go back to reference Tersmette AC, Petersen GM, Offerhaus GJ et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738–744PubMed Tersmette AC, Petersen GM, Offerhaus GJ et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738–744PubMed
12.
go back to reference Hruban RH, Petersen GM, Goggins M et al (1999) Familial pancreatic cancer. Ann Oncol 10(Suppl 4):69–73PubMedCrossRef Hruban RH, Petersen GM, Goggins M et al (1999) Familial pancreatic cancer. Ann Oncol 10(Suppl 4):69–73PubMedCrossRef
13.
go back to reference Bartsch DK, Kress R, Sina-Frey M et al (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110:902–906PubMedCrossRef Bartsch DK, Kress R, Sina-Frey M et al (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110:902–906PubMedCrossRef
14.
go back to reference Hemminki K, Li X (2003) Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 103:525–530PubMedCrossRef Hemminki K, Li X (2003) Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 103:525–530PubMedCrossRef
15.
go back to reference Hahn SA, Greenhalf B, Ellis I et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221PubMedCrossRef Hahn SA, Greenhalf B, Ellis I et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221PubMedCrossRef
16.
go back to reference Bartsch DK, Fendrich V, Slater EP et al (2005) RNASEL germline variants are associated with pancreatic cancer. Int J Cancer 117:718–722PubMedCrossRef Bartsch DK, Fendrich V, Slater EP et al (2005) RNASEL germline variants are associated with pancreatic cancer. Int J Cancer 117:718–722PubMedCrossRef
17.
go back to reference Bartsch DK, Krysewski K, Sina-Frey M et al (2006) Low frequency of CHEK2 mutations in familial pancreatic cancer. Fam Cancer 5:305–308PubMedCrossRef Bartsch DK, Krysewski K, Sina-Frey M et al (2006) Low frequency of CHEK2 mutations in familial pancreatic cancer. Fam Cancer 5:305–308PubMedCrossRef
18.
go back to reference Bartsch DK, Sina-Frey M, Lang S et al (2002) CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236:730–737PubMedCrossRef Bartsch DK, Sina-Frey M, Lang S et al (2002) CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236:730–737PubMedCrossRef
19.
go back to reference Grutzmann R, McFaul C, Bartsch DK et al (2004) No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. Cancer Lett 214:63–68PubMedCrossRef Grutzmann R, McFaul C, Bartsch DK et al (2004) No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. Cancer Lett 214:63–68PubMedCrossRef
20.
go back to reference Nej K, Bartsch DK, Sina-Frey M et al (2004) The NOD23020insC mutation and the risk of familial pancreatic cancer? Hered Cancer Clin Pract 2:149–150PubMedCrossRef Nej K, Bartsch DK, Sina-Frey M et al (2004) The NOD23020insC mutation and the risk of familial pancreatic cancer? Hered Cancer Clin Pract 2:149–150PubMedCrossRef
21.
go back to reference Slater E, Amrillaeva V, Fendrich V et al (2007) Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med 4:e164PubMedCrossRef Slater E, Amrillaeva V, Fendrich V et al (2007) Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med 4:e164PubMedCrossRef
22.
go back to reference Slater EP, Langer P, Habbe N et al. (2010) Prevalence of PALB2 mutations in familial pancreatic cancer. Clin Genet (in press) Slater EP, Langer P, Habbe N et al. (2010) Prevalence of PALB2 mutations in familial pancreatic cancer. Clin Genet (in press)
23.
go back to reference Bartsch DK, Langer P, Habbe N et al. (2009) Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. Clin Genet 77:333–341PubMedCrossRef Bartsch DK, Langer P, Habbe N et al. (2009) Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families. Clin Genet 77:333–341PubMedCrossRef
24.
go back to reference McFaul CD, Greenhalf W, Earl J et al (2006) Anticipation in familial pancreatic cancer. Gut 55:252–258PubMedCrossRef McFaul CD, Greenhalf W, Earl J et al (2006) Anticipation in familial pancreatic cancer. Gut 55:252–258PubMedCrossRef
25.
go back to reference Slater EP, Langer P, Fendrich V et al. (2010) Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 9:335–343PubMedCrossRef Slater EP, Langer P, Fendrich V et al. (2010) Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 9:335–343PubMedCrossRef
26.
go back to reference Langer P, Kann PH, Fendrich V et al (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58:1410–1418PubMedCrossRef Langer P, Kann PH, Fendrich V et al (2009) Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58:1410–1418PubMedCrossRef
27.
go back to reference Lynch HT, Fusaro L, Smyrk TC et al (1995) Medical genetic study of eight pancreatic cancer-prone families. Cancer Invest 13:141–149PubMedCrossRef Lynch HT, Fusaro L, Smyrk TC et al (1995) Medical genetic study of eight pancreatic cancer-prone families. Cancer Invest 13:141–149PubMedCrossRef
28.
go back to reference Greenhalf W, Malats N, Nilsson M et al (2008) International registries of families at high risk of pancreatic cancer. Pancreatology 8:558–565PubMedCrossRef Greenhalf W, Malats N, Nilsson M et al (2008) International registries of families at high risk of pancreatic cancer. Pancreatology 8:558–565PubMedCrossRef
29.
go back to reference Schuz J, Schon D, Batzler W et al (2000) Cancer registration in Germany: current status, perspectives and trends in cancer incidence 1973–93. J Epidemiol Biostat 5:99–107PubMed Schuz J, Schon D, Batzler W et al (2000) Cancer registration in Germany: current status, perspectives and trends in cancer incidence 1973–93. J Epidemiol Biostat 5:99–107PubMed
30.
go back to reference Murphy KM, Brune KA, Griffin C et al (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789–3793PubMed Murphy KM, Brune KA, Griffin C et al (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789–3793PubMed
31.
go back to reference Couch FJ, Johnson MR, Rabe KG et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomark Prev 16:342–346CrossRef Couch FJ, Johnson MR, Rabe KG et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomark Prev 16:342–346CrossRef
32.
go back to reference Jones S, Hruban RH, Kamiyama M et al (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217PubMedCrossRef Jones S, Hruban RH, Kamiyama M et al (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217PubMedCrossRef
33.
go back to reference Pogue-Geile KL, Chen R, Bronner MP et al (2006) Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 3:e516PubMedCrossRef Pogue-Geile KL, Chen R, Bronner MP et al (2006) Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 3:e516PubMedCrossRef
34.
go back to reference Earl J, Yan L, Vitone LJ et al (2006) Evaluation of the 4q32–34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomark Prev 15:1948–1955CrossRef Earl J, Yan L, Vitone LJ et al (2006) Evaluation of the 4q32–34 locus in European familial pancreatic cancer. Cancer Epidemiol Biomark Prev 15:1948–1955CrossRef
35.
go back to reference Brand RE (2009) Screening for familial pancreatic cancer: is doing something better than doing nothing? Gut 58:1321–1322PubMedCrossRef Brand RE (2009) Screening for familial pancreatic cancer: is doing something better than doing nothing? Gut 58:1321–1322PubMedCrossRef
36.
go back to reference Canto MI, Goggins M, Yeo CJ et al (2004) Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2:606–621PubMedCrossRef Canto MI, Goggins M, Yeo CJ et al (2004) Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2:606–621PubMedCrossRef
37.
go back to reference Canto MI, Goggins M, Hruban RH et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766–781PubMedCrossRef Canto MI, Goggins M, Hruban RH et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766–781PubMedCrossRef
38.
go back to reference Poley JW, Kluijt I, Gouma DJ et al (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104:2175–2181PubMedCrossRef Poley JW, Kluijt I, Gouma DJ et al (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104:2175–2181PubMedCrossRef
39.
go back to reference Brentnall TA (2005) Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 6:437–445PubMedCrossRef Brentnall TA (2005) Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 6:437–445PubMedCrossRef
Metadata
Title
German national case collection for familial pancreatic cancer (FaPaCa): ten years experience
Authors
Ralph Schneider
Emily P. Slater
Mercede Sina
Nils Habbe
Volker Fendrich
Elvira Matthäi
Peter Langer
Detlef K. Bartsch
Publication date
01-06-2011
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2011
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9414-x

Other articles of this Issue 2/2011

Familial Cancer 2/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine